12:15 PM EDT, 05/21/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our 12-month target price of $99, 17.7x our FY 26 EPS (Apr.) estimate, a small premium to MDT's historical forward average due to our expectation of margin expansion. We trim our FY 26 EPS forecast to $5.59 from $5.82 and start FY 27 at $6.27. Apr-Q EPS of $1.62 vs. $1.46 was $0.04 above consensus. Revenue increased 3.9% Y/Y to $8.93B, which was ahead of consensus, and up 5.4% on an organic basis, driven by strong performances in Cardiac Ablation Solutions, Diabetes, and Neuroscience segments, partially offset by weaker performance in Medical Surgical. On the profitability side, operating margin increased 90 bps Y/Y to 27.8%. MDT is guiding for FY 26 EPS in the $5.50-$5.60 range, as EPS guidance incorporates MDT's view of anticipated tariff scenarios with China. MDT also announced intention to spin-off its Diabetes segment into a stand-alone company, which we think makes strategic sense as the business is different from MDT's core businesses and the two companies may be valued higher independently than as a unit.